Samsung Bioepis Introduces Denosumab Biosimilars OBODENCE™ and XBRYK™ to European Market
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in…
Janux Reports Promising Phase 1 Results for JANX007 in mCRPC
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through…
AltPep Shows SOBIN-AD Peptide Improves Alzheimer’s Behavior in Preclinical Study at CTAD 2025
AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to…
Cellares Names Ali Soleymannezhad as CCO to Drive Global Expansion and IPO Prep
Cellares Appoints Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion and Drive Cell Therapy Access Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) transforming the cell…
Vistagen Announces Appointment of Nick Tressler as Chief Financial Officer
Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through…
Octave Bioscience Partners with Quest Diagnostics to Expand MSDA Test Access
Octave Bioscience Partners with Quest Diagnostics to Expand Nationwide Access to MSDA Test Octave Bioscience, a commercial-stage precision care company at the forefront of redefining disease management in multiple sclerosis…
Omeros Corporation Finalizes Asset Purchase and License Agreement with Novo Nordisk for MASP-3 Inhibitor Zaltenibart
Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed…
Mirum Pharmaceuticals Begins BLOOM Phase 2 Trial with First Patient Dosed Evaluating MRM-3379 for Fragile X Syndrome
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for…
Incyte Names Richard Hoffman Executive Vice President and General Counsel
Incyte Announces Appointment of Richard Hoffman as Executive Vice President and General Counsel Incyte today announced that Richard Hoffman has officially assumed the role of Executive Vice President and General…
Circle Pharma Announces Appointment of Dr. Anne E. Borgman as CMO
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer, Strengthening Leadership Team to Advance Next-Generation Macrocycle Oncology Pipeline Circle Pharma, Inc., a clinical-stage biopharmaceutical company advancing a new…
Agilent Unveils 21 CFR Part 11–Compliant Software for xCELLigence RTCA eSight
Agilent Launches Compliance Software for xCELLigence RTCA eSight to Meet 21 CFR Part 11 Standards Agilent Technologies Inc., a global leader in analytical instrumentation, diagnostics, and scientific innovation, has announced…
TeamBest Global Issues Open Letter to AROI on Affordable Cancer and Vascular Care
TeamBest Global Calls for Stronger Collaboration with AROI to Advance Affordable Cancer and Vascular Disease Care in India and Worldwide Dr. Krishnan Suthanthiran, along with his TeamBest Global family of…